knowledge -WSS

knowledge

author：comprehensive 2025-08-25 16:34:07 - browse：5

New Sanofi Genzyme president Bill Sibold is the first person without any ties to Henri Termeer (inset) to lead the company. Jonathan Wiggs/Globe staff

CAMBRIDGE, Mass. — When drug giant Sanofi restructured its global business two years ago, its Genzyme division got a new name, Sanofi Genzyme, explicitly tying it to the French parent company. It also got new responsibilities and a larger “specialty care” portfolio covering everything from enzyme replacement to cancer and multiple sclerosis drugs.

Last week, Sanofi Genzyme — still the largest Massachusetts biotech, with about 5,000 workers — also got a new president, Bill Sibold. He’s the first one without any ties to the old Genzyme, an independent company that pioneered the rare-disease business model and catalyzed the local life sciences boom before accepting Sanofi’s $20.1 billion takeover offer in 2011.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： How one medical school became remarkably diverse
Next article： Why Charlie Gard's case is so disturbing to Americans

knowledge

entertainment

Wikipedia

WSS

Sana to lay off nearly a third of staff, de

Colorectal cancer study finds potential in overlooked immune cell

A new study asks: Are we harming blood donors by taking blood?

Brain 'hot spot' may explain why African Americans feel greater pain

7 people shot in DC, police say

Meta looks to target Twitter with a rival app called Threads

focus

knowledge

focus

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

What does generative AI mean for health care? We asked experts

Why Charlie Gard's case is so disturbing to Americans

At least 13 dead in Texas as scorching temps continue

FDA rejects Alnylam's heart disease treatment over insufficient data

Drug repurposing or repositioning? The language matters

Grail is spending more than ever lobbying Congress

Drug repurposing or repositioning? The language matters

Physician executives need more than on

hotspot

Ukraine, Russia accuse each other of planning to attack Europe's biggest nuclear plant

Eli Lilly buys Point Biopharma in radiopharmaceuticals play

Why is France rioting? What to know about the fatal police shooting of Nahel M

A Q&A with the global head of Boehringer Ingelheim's innovation unit

FDA panel signals lack of confidence in Amgen cancer drug data

A virus, fished out of a lake, may have saved a man’s life

knowledge

entertainment

Wikipedia

focus